ASCO 2015: New Ibrutinib Combination Regimen Shows Substantial Benefits in Relapsed Chronic Lymphocytic Leukemia
An interim analysis of a large phase III study suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes for patients with chronic-lymphocytic leukemia (CLL) that wo...
Author: EMJ
Added: 06/03/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Rituxan | Study | Treanda